These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia. Kanagasabay RR; Unsworth-White MJ; Robinson G; Bevan D; Farnsworth G; Haxby EJ; Smith EE Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413 [TBL] [Abstract][Full Text] [Related]
8. Thromboembolic prophylaxis with danaparoïd (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease. Macchi L; Sarfati R; Guicheteau M; Chamlian V; Pourrat O; Gruel Y; Magnin G; Brizard A; Boinot C Clin Appl Thromb Hemost; 2000 Oct; 6(4):187-9. PubMed ID: 11030522 [TBL] [Abstract][Full Text] [Related]
9. The use of danaparoid to manage coagulopathy in a neurosurgical patient with heparin-induced thrombocytopenia type II and intracerebral haemorrhage. Hertle DN; Hähnel S; Richter GM; Unterberg A; Sakowitz OW; Kiening KL Br J Neurosurg; 2011 Feb; 25(1):117-9. PubMed ID: 20707682 [TBL] [Abstract][Full Text] [Related]
10. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Magnani HN Thromb Haemost; 1993 Oct; 70(4):554-61. PubMed ID: 7509508 [TBL] [Abstract][Full Text] [Related]
11. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Ortel TL; Gockerman JP; Califf RM; McCann RL; O'Connor CM; Metzler DM; Greenberg CS Thromb Haemost; 1992 Mar; 67(3):292-6. PubMed ID: 1379384 [TBL] [Abstract][Full Text] [Related]
12. [Current treatment concepts in heparin-induced thrombocytopenia]. Ranze O; Greinacher A Dtsch Med Wochenschr; 1999 Jul; 124(28-29):865-73. PubMed ID: 10432950 [No Abstract] [Full Text] [Related]
13. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations. Hill GR; Hickton C; Henderson S; Patton WN Clin Lab Haematol; 1997 Jun; 19(2):155-7. PubMed ID: 9218159 [TBL] [Abstract][Full Text] [Related]
14. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases. Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218 [TBL] [Abstract][Full Text] [Related]
15. Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia Type II (HIT). Gerhardt A; Scharf RE; Zotz RB Clin Appl Thromb Hemost; 2009; 15(4):461-4. PubMed ID: 18840630 [TBL] [Abstract][Full Text] [Related]
16. Delayed-type hypersensitivity to subcutaneous heparin with tolerance of i.v. administration. Liew G; Campbell C; Thursby P ANZ J Surg; 2004 Nov; 74(11):1020-1. PubMed ID: 15550103 [No Abstract] [Full Text] [Related]
17. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264 [TBL] [Abstract][Full Text] [Related]
18. [Heparin-induced thrombocytopenia--a serious complication within the scope of heparin therapy. Follow-up of 7 trauma surgery patients]. Kuhn B Unfallchirurg; 1997 Aug; 100(8):646-51. PubMed ID: 9381213 [TBL] [Abstract][Full Text] [Related]
19. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome? Kikta MJ; Keller MP; Humphrey PW; Silver D Surgery; 1993 Oct; 114(4):705-10. PubMed ID: 7692613 [TBL] [Abstract][Full Text] [Related]